Compounds > n-caffeoyltyramine
Page last updated: 2024-11-12

n-caffeoyltyramine

Description Research Excerpts Clinical Trials Roles Classes Pathways Study Profile Bioassays Related Drugs Related Conditions Protein Interactions Research Growth Market Indicators

Description

N-caffeoyltyramine: structure in first source [Medical Subject Headings (MeSH), National Library of Medicine, extracted Dec-2023]

Cross-References

ID SourceID
PubMed CID9994897
CHEMBL ID206646
CHEBI ID193479
SCHEMBL ID1916311
MeSH IDM0460691

Synonyms (33)

Synonym
y13 ,
(2e)-3-(3,4-dihydroxyphenyl)-n-[2-(4-hydroxyphenyl)ethyl]acrylamide
NCGC00180274-01
ACON1_001661
2EW6
MEGXP0_001140
n-trans-caffeoyltyramine
n-caffeoyltyramine
DB08754
typheramide
trans-n-caffeoyltyramine
CHEMBL206646
CHEBI:193479
103188-48-3
(e)-3-(3,4-dihydroxyphenyl)-n-[2-(4-hydroxyphenyl)ethyl]prop-2-enamide
n-cis-caffeoyltyramine
SCHEMBL1916311
n-(e)-caffeoyl-.lambda.-tyramine
unii-3lz974dq9j
n-(e)-caffeoyl-lambda-tyramine
3lz974dq9j ,
(2e)-3-(3,4-dihydroxyphenyl)-n-(2-(4-hydroxyphenyl)ethyl)-2-propenamide
AC-35174
(2e)-3-(3,4-dihydroxyphenyl)-n-[2-(4-hydroxyphenyl)ethyl]prop-2-enamide
n-trans-caffeoyltyramine, >=85% (lc/ms-elsd)
(e)-3-(3,4-dihydroxyphenyl)-n-(4-hydroxyphenethyl)acrylamide
Q27097940
VSHUQLRHTJOKTA-XBXARRHUSA-N
MS-24306
E88905
CS-0140504
AKOS040763479
HY-N8241
[information is derived through text-mining from research data collected from National Library of Medicine (NLM), extracted Dec-2023]

Drug Classes (1)

ClassDescription
catecholsAny compound containing an o-diphenol component.
[compound class information is derived from Chemical Entities of Biological Interest (ChEBI), Hastings J, Owen G, Dekker A, Ennis M, Kale N, Muthukrishnan V, Turner S, Swainston N, Mendes P, Steinbeck C. (2016). ChEBI in 2016: Improved services and an expanding collection of metabolites. Nucleic Acids Res]

Protein Targets (2)

Inhibition Measurements

ProteinTaxonomyMeasurementAverageMin (ref.)Avg (ref.)Max (ref.)Bioassay(s)
Chain A, peptide deformylaseHelicobacter pyloriIC50 (µMol)10.800010.800010.800010.8000AID977608
Chain A, peptide deformylaseHelicobacter pyloriIC50 (µMol)10.800010.800010.800010.8000AID977608
[prepared from compound, protein, and bioassay information from National Library of Medicine (NLM), extracted Dec-2023]

Bioassays (31)

Assay IDTitleYearJournalArticle
AID263691DPPH radical scavenging activity at 100 uM2006Bioorganic & medicinal chemistry letters, Apr-15, Volume: 16, Issue:8
Analogues of N-hydroxycinnamoylphenalkylamides as inhibitors of human melanocyte-tyrosinase.
AID428339Cytotoxicity against mouse B16 cells assessed as cell viability at 10 to 30 uM after 2 days by tetrazolium reduction assay2009Bioorganic & medicinal chemistry letters, Aug-01, Volume: 19, Issue:15
N-[(Dihydroxyphenyl)acyl]serotonins as potent inhibitors of tyrosinase from mouse and human melanoma cells.
AID1811145Antialzheimer activity in mouse N2a-APP cells assessed as reduction of BACE-1 expression at 0.03 to 0.08 uM measured after 48 hrs by RT-qPCR method2021Journal of natural products, 09-24, Volume: 84, Issue:9
Dual Role of Phenyl Amides from Hempseed on BACE 1, PPARγ, and PGC-1α in N2a-APP Cells.
AID428332Inhibition of catecholase activity of tyrosinase in mouse B16 cells assessed as dopachrome formation2009Bioorganic & medicinal chemistry letters, Aug-01, Volume: 19, Issue:15
N-[(Dihydroxyphenyl)acyl]serotonins as potent inhibitors of tyrosinase from mouse and human melanoma cells.
AID263688Inhibitory activity against tyrosinase at 100uM2006Bioorganic & medicinal chemistry letters, Apr-15, Volume: 16, Issue:8
Analogues of N-hydroxycinnamoylphenalkylamides as inhibitors of human melanocyte-tyrosinase.
AID1293692Inhibition of alpha-amylase (unknown origin) up to 200 uM2016European journal of medicinal chemistry, May-23, Volume: 114Cinnamic acid amides from Tribulus terrestris displaying uncompetitive α-glucosidase inhibition.
AID1293689Uncompetitive inhibition of baker's yeast alpha-glucosidase using pNPG as substrate by Cornish-Bowden plot analysis2016European journal of medicinal chemistry, May-23, Volume: 114Cinnamic acid amides from Tribulus terrestris displaying uncompetitive α-glucosidase inhibition.
AID1293688Inhibition of baker's yeast alpha-glucosidase using pNPG as substrate by spectrophotometry2016European journal of medicinal chemistry, May-23, Volume: 114Cinnamic acid amides from Tribulus terrestris displaying uncompetitive α-glucosidase inhibition.
AID1293691Inhibition of alpha-mannosidase (unknown origin) up to 200 uM2016European journal of medicinal chemistry, May-23, Volume: 114Cinnamic acid amides from Tribulus terrestris displaying uncompetitive α-glucosidase inhibition.
AID1811142Cytotoxicity against mouse N2a-APP cells assessed as cell viability at 0.03 to 0.08 uM measured after 24 hrs by MTT assay2021Journal of natural products, 09-24, Volume: 84, Issue:9
Dual Role of Phenyl Amides from Hempseed on BACE 1, PPARγ, and PGC-1α in N2a-APP Cells.
AID1293690Inhibition of alpha-galactosidase (unknown origin) up to 200 uM2016European journal of medicinal chemistry, May-23, Volume: 114Cinnamic acid amides from Tribulus terrestris displaying uncompetitive α-glucosidase inhibition.
AID1811143Cytotoxicity against mouse N2a-APP cells assessed as cell viability at 0.03 to 0.08 uM measured after 48 hrs by MTT assay2021Journal of natural products, 09-24, Volume: 84, Issue:9
Dual Role of Phenyl Amides from Hempseed on BACE 1, PPARγ, and PGC-1α in N2a-APP Cells.
AID263690Toxicity in rat at 2 g/kg, po2006Bioorganic & medicinal chemistry letters, Apr-15, Volume: 16, Issue:8
Analogues of N-hydroxycinnamoylphenalkylamides as inhibitors of human melanocyte-tyrosinase.
AID428336Cytotoxicity against mouse B16 cells assessed as cell viability at 20 uM after 2 days by tetrazolium reduction assay2009Bioorganic & medicinal chemistry letters, Aug-01, Volume: 19, Issue:15
N-[(Dihydroxyphenyl)acyl]serotonins as potent inhibitors of tyrosinase from mouse and human melanoma cells.
AID428334Inhibition of catecholase activity of tyrosinase in human HMVII cells assessed as dopachrome formation at 100 uM2009Bioorganic & medicinal chemistry letters, Aug-01, Volume: 19, Issue:15
N-[(Dihydroxyphenyl)acyl]serotonins as potent inhibitors of tyrosinase from mouse and human melanoma cells.
AID1811141Permeability of compound assessed as retention time by PAMPA-BBB assay2021Journal of natural products, 09-24, Volume: 84, Issue:9
Dual Role of Phenyl Amides from Hempseed on BACE 1, PPARγ, and PGC-1α in N2a-APP Cells.
AID1625410Cytotoxicity against human KB cells by sulforhodamine B assay2016Journal of natural products, Apr-22, Volume: 79, Issue:4
Antimalarial Oxoprotoberberine Alkaloids from the Leaves of Miliusa cuneata.
AID1811146Antialzheimer activity in mouse N2a-APP cells assessed as increase of PARP-gamma expression at 0.03 to 0.08 uM measured after 24 hrs by RT-qPCR method2021Journal of natural products, 09-24, Volume: 84, Issue:9
Dual Role of Phenyl Amides from Hempseed on BACE 1, PPARγ, and PGC-1α in N2a-APP Cells.
AID428335Antimelanogenic activity in mouse B16 cells assessed as inhibition of intracellular melanin accumulation after 2 days2009Bioorganic & medicinal chemistry letters, Aug-01, Volume: 19, Issue:15
N-[(Dihydroxyphenyl)acyl]serotonins as potent inhibitors of tyrosinase from mouse and human melanoma cells.
AID1625411Cytotoxicity against African green monkey Vero cells by sulforhodamine B assay2016Journal of natural products, Apr-22, Volume: 79, Issue:4
Antimalarial Oxoprotoberberine Alkaloids from the Leaves of Miliusa cuneata.
AID1811149Antialzheimer activity in mouse N2a-APP cells assessed as up-regulation of PGC-1alpha expression at 0.03 to 0.08 uM measured after 24 to 48 hrs by RT-qPCR method2021Journal of natural products, 09-24, Volume: 84, Issue:9
Dual Role of Phenyl Amides from Hempseed on BACE 1, PPARγ, and PGC-1α in N2a-APP Cells.
AID1811144Antialzheimer activity in mouse N2a-APP cells assessed as reduction of BACE-1 expression at 0.03 to 0.08 uM measured after 24 hrs by RT-qPCR method2021Journal of natural products, 09-24, Volume: 84, Issue:9
Dual Role of Phenyl Amides from Hempseed on BACE 1, PPARγ, and PGC-1α in N2a-APP Cells.
AID1625413Antiplasmodial activity against multidrug-resistant Plasmodium falciparum K1 infected in human RBC incubated for 18 to 20 hrs by microdilution radioisotope method2016Journal of natural products, Apr-22, Volume: 79, Issue:4
Antimalarial Oxoprotoberberine Alkaloids from the Leaves of Miliusa cuneata.
AID428333Inhibition of catecholase activity of tyrosinase in mouse B16 cells assessed as dopachrome formation at 100 uM2009Bioorganic & medicinal chemistry letters, Aug-01, Volume: 19, Issue:15
N-[(Dihydroxyphenyl)acyl]serotonins as potent inhibitors of tyrosinase from mouse and human melanoma cells.
AID731498Antioxidant activity assessed as inhibition of xanthine-xanthine oxidase generated superoxide anion radical production by NBT reduction assay2013Journal of natural products, Jan-25, Volume: 76, Issue:1
Neolignanamides, lignanamides, and other phenolic compounds from the root bark of Lycium chinense.
AID1625412Antiplasmodial activity against chloroquine/antifolate-sensitive Plasmodium falciparum TM4 infected in human RBC incubated for 18 to 20 hrs by microdilution radioisotope method2016Journal of natural products, Apr-22, Volume: 79, Issue:4
Antimalarial Oxoprotoberberine Alkaloids from the Leaves of Miliusa cuneata.
AID1811147Antialzheimer activity in mouse N2a-APP cells assessed as increase of PARP-gamma expression at 0.03 to 0.08 uM measured after 48 hrs by RT-qPCR method2021Journal of natural products, 09-24, Volume: 84, Issue:9
Dual Role of Phenyl Amides from Hempseed on BACE 1, PPARγ, and PGC-1α in N2a-APP Cells.
AID731499Antioxidant activity assessed as DPPH radical scavenging activity after 30 mins2013Journal of natural products, Jan-25, Volume: 76, Issue:1
Neolignanamides, lignanamides, and other phenolic compounds from the root bark of Lycium chinense.
AID1293687Inhibition of beta-glucosidase (unknown origin) up to 200 uM2016European journal of medicinal chemistry, May-23, Volume: 114Cinnamic acid amides from Tribulus terrestris displaying uncompetitive α-glucosidase inhibition.
AID977608Experimentally measured binding affinity data (IC50) for protein-ligand complexes derived from PDB2006Protein science : a publication of the Protein Society, Sep, Volume: 15, Issue:9
Peptide deformylase is a potential target for anti-Helicobacter pylori drugs: reverse docking, enzymatic assay, and X-ray crystallography validation.
AID1811Experimentally measured binding affinity data derived from PDB2006Protein science : a publication of the Protein Society, Sep, Volume: 15, Issue:9
Peptide deformylase is a potential target for anti-Helicobacter pylori drugs: reverse docking, enzymatic assay, and X-ray crystallography validation.
[information is prepared from bioassay data collected from National Library of Medicine (NLM), extracted Dec-2023]

Research

Studies (15)

TimeframeStudies, This Drug (%)All Drugs %
pre-19900 (0.00)18.7374
1990's0 (0.00)18.2507
2000's7 (46.67)29.6817
2010's6 (40.00)24.3611
2020's2 (13.33)2.80
[information is prepared from research data collected from National Library of Medicine (NLM), extracted Dec-2023]

Market Indicators

Research Demand Index: 11.81

According to the monthly volume, diversity, and competition of internet searches for this compound, as well the volume and growth of publications, there is estimated to be weak demand-to-supply ratio for research on this compound.

MetricThis Compound (vs All)
Research Demand Index11.81 (24.57)
Research Supply Index2.77 (2.92)
Research Growth Index4.58 (4.65)
Search Engine Demand Index0.00 (26.88)
Search Engine Supply Index0.00 (0.95)

This Compound (11.81)

All Compounds (24.57)

Study Types

Publication TypeThis drug (%)All Drugs (%)
Trials0 (0.00%)5.53%
Reviews0 (0.00%)6.00%
Case Studies0 (0.00%)4.05%
Observational0 (0.00%)0.25%
Other15 (100.00%)84.16%
[information is prepared from research data collected from National Library of Medicine (NLM), extracted Dec-2023]
SubstanceRelationship StrengthStudiesTrialsClassesRoles
dihydroxyphenylalanine
Dihydroxyphenylalanine: A beta-hydroxylated derivative of phenylalanine. The D-form of dihydroxyphenylalanine has less physiologic activity than the L-form and is commonly used experimentally to determine whether the pharmacological effects of LEVODOPA are stereospecific.. dopa : A hydroxyphenylalanine carrying hydroxy substituents at positions 3 and 4 of the benzene ring.		2.0310hydroxyphenylalanine;
non-proteinogenic alpha-amino acid;
tyrosine derivative		human metabolite
n-acetylserotonin
N-acetylserotonin : An N-acylserotonin resulting from the formal condensation of the primary amino group of serotonin with the carboxy group of acetic acid.		2.0510acetamides;
N-acylserotonin;
phenols		antioxidant;
human metabolite;
mouse metabolite;
tropomyosin-related kinase B receptor agonist
chloroquine
Chloroquine: The prototypical antimalarial agent with a mechanism that is not well understood. It has also been used to treat rheumatoid arthritis, systemic lupus erythematosus, and in the systemic therapy of amebic liver abscesses.. chloroquine : An aminoquinoline that is quinoline which is substituted at position 4 by a [5-(diethylamino)pentan-2-yl]amino group at at position 7 by chlorine. It is used for the treatment of malaria, hepatic amoebiasis, lupus erythematosus, light-sensitive skin eruptions, and rheumatoid arthritis.		2.1310aminoquinoline;
organochlorine compound;
secondary amino compound;
tertiary amino compound		anticoronaviral agent;
antimalarial;
antirheumatic drug;
autophagy inhibitor;
dermatologic drug
ellipticine
ellipticine : A organic heterotetracyclic compound that is pyrido[4,3-b]carbazole carrying two methyl substituents at positions 5 and 11.		2.1310indole alkaloid;
organic heterotetracyclic compound;
organonitrogen heterocyclic compound;
polycyclic heteroarene		antineoplastic agent;
plant metabolite
kojic acid
[no description available]		2.44204-pyranones;
enol;
primary alcohol		Aspergillus metabolite;
EC 1.10.3.1 (catechol oxidase) inhibitor;
EC 1.10.3.2 (laccase) inhibitor;
EC 1.13.11.24 (quercetin 2,3-dioxygenase) inhibitor;
EC 1.14.18.1 (tyrosinase) inhibitor;
EC 1.4.3.3 (D-amino-acid oxidase) inhibitor;
NF-kappaB inhibitor;
skin lightening agent
octopamine
Octopamine: An alpha-adrenergic sympathomimetic amine, biosynthesized from tyramine in the CNS and platelets and also in invertebrate nervous systems. It is used to treat hypotension and as a cardiotonic. The natural D(-) form is more potent than the L(+) form in producing cardiovascular adrenergic responses. It is also a neurotransmitter in some invertebrates.. octopamine : A member of the class of phenylethanolamines that is phenol which is substituted at the para- position by a 2-amino-1-hydroxyethyl group. A biogenic phenylethanolamine which has been found to act as a neurotransmitter, neurohormone or neuromodulator in invertebrates.		2.0210phenylethanolamines;
tyramines		neurotransmitter
pyrimethamine
Maloprim: contains above 2 cpds		2.1310aminopyrimidine;
monochlorobenzenes		antimalarial;
antiprotozoal drug;
EC 1.5.1.3 (dihydrofolate reductase) inhibitor
tyramine
[no description available]		3.6790monoamine molecular messenger;
primary amino compound;
tyramines		EC 3.1.1.8 (cholinesterase) inhibitor;
Escherichia coli metabolite;
human metabolite;
mouse metabolite;
neurotransmitter
levodopa
Levodopa: The naturally occurring form of DIHYDROXYPHENYLALANINE and the immediate precursor of DOPAMINE. Unlike dopamine itself, it can be taken orally and crosses the blood-brain barrier. It is rapidly taken up by dopaminergic neurons and converted to DOPAMINE. It is used for the treatment of PARKINSONIAN DISORDERS and is usually given with agents that inhibit its conversion to dopamine outside of the central nervous system.. L-dopa : An optically active form of dopa having L-configuration. Used to treat the stiffness, tremors, spasms, and poor muscle control of Parkinson's disease		2.0310amino acid zwitterion;
dopa;
L-tyrosine derivative;
non-proteinogenic L-alpha-amino acid		allelochemical;
antidyskinesia agent;
antiparkinson drug;
dopaminergic agent;
hapten;
human metabolite;
mouse metabolite;
neurotoxin;
plant growth retardant;
plant metabolite;
prodrug
tyrosine
Tyrosine: A non-essential amino acid. In animals it is synthesized from PHENYLALANINE. It is also the precursor of EPINEPHRINE; THYROID HORMONES; and melanin.. tyrosine : An alpha-amino acid that is phenylalanine bearing a hydroxy substituent at position 4 on the phenyl ring.		7.4220amino acid zwitterion;
erythrose 4-phosphate/phosphoenolpyruvate family amino acid;
L-alpha-amino acid;
proteinogenic amino acid;
tyrosine		EC 1.3.1.43 (arogenate dehydrogenase) inhibitor;
fundamental metabolite;
micronutrient;
nutraceutical
cycloguanil
cycloguanil: the active metabolite of proguanil; antifolate drug; structure in first source. cycloguanil : A triazine in which a 1,6-dihydro-1,3,5-triazine ring is substituted at N-1 by a 4-chlorophenyl group, at C-2 and -4 by amino groups and at C-6 by gem-dimethyl groups. A dihydrofolate reductase inhibitor, it is a metabolite of the antimalarial drug proguanil.		2.1310triazinesantifolate;
antiinfective agent;
antimalarial;
antiparasitic agent;
antiprotozoal drug;
EC 1.5.1.3 (dihydrofolate reductase) inhibitor
malondialdehyde
Malondialdehyde: The dialdehyde of malonic acid.. malonaldehyde : A dialdehyde that is propane substituted by two oxo groups at the terminal carbon atoms respectively. A biomarker of oxidative damage to lipids caused by smoking, it exists in vivo mainly in the enol form.		2.1510dialdehydebiomarker
5-hydroxyindole
[no description available]		2.0510hydroxyindoleshuman metabolite
1-deoxynojirimycin
1-deoxy-nojirimycin: structure in first source. duvoglustat : An optically active form of 2-(hydroxymethyl)piperidine-3,4,5-triol having 2R,3R,4R,5S-configuration.		2.13102-(hydroxymethyl)piperidine-3,4,5-triol;
piperidine alkaloid		anti-HIV agent;
anti-obesity agent;
bacterial metabolite;
EC 3.2.1.20 (alpha-glucosidase) inhibitor;
hepatoprotective agent;
hypoglycemic agent;
plant metabolite
6-hydroxy-2,5,7,8-tetramethylchroman-2-carboxylic acid
[no description available]		2.0810chromanol;
monocarboxylic acid;
phenols		antioxidant;
ferroptosis inhibitor;
neuroprotective agent;
radical scavenger;
Wnt signalling inhibitor
dopaquinone
[no description available]		2.03101,2-benzoquinones;
amino acid zwitterion;
L-phenylalanine derivative		human metabolite;
mouse metabolite
syringaresinol
(+)-syringaresinol : The (7alpha,7'alpha,8alpha,8'alpha)-stereoisomer of syringaresinol.		2.1310syringaresinolantineoplastic agent
ferulic acid
ferulate : A monocarboxylic acid anion obtained by the deprotonation of the carboxy group of ferulic acid.		2.0310ferulic acidsanti-inflammatory agent;
antioxidant;
apoptosis inhibitor;
cardioprotective agent;
MALDI matrix material;
plant metabolite
trans-4-coumaric acid
hydroxycinnamic acid : Any member of the class of cinnamic acids carrying one or more hydroxy substituents.. trans-4-coumaric acid : The trans-isomer of 4-coumaric acid.. 4-coumaric acid : A coumaric acid in which the hydroxy substituent is located at C-4 of the phenyl ring.		2.03104-coumaric acidfood component;
mouse metabolite;
plant metabolite
caffeic acid
trans-caffeic acid : The trans-isomer of caffeic acid.		2.0310caffeic acidgeroprotector;
mouse metabolite
feruloyltyramine
feruloyltyramine: structure given in first source; isolated from Cannabis sativa seeds, roots, leaves, and resin; induces hypothermia and motor incoordination in mice; moupinamide is (E)-isomer		3.4970tyraminesmetabolite
chrysosplenetin b
chrysosplenetin B: constituent of the root of Berneuxia thibetica Decne. chrysosplenetin : A tetramethoxyflavone that is the 3,6,7,3'-tetramethyl ether derivative of quercetagetin.		2.1310dihydroxyflavone;
tetramethoxyflavone		antiviral agent;
plant metabolite
pachypodol
pachypodol: new flavonoid isolated from Pachypodanthium confine; from Chinese herb Agastache folium; structure. pachypodol : A trimethoxyflavone that is quercetin in which the hydroxy groups at position 3, 7 and 3' are replaced by methoxy groups. It has been isolated from Combretum quadrangulare and Euodia elleryana.		2.1310dihydroxyflavone;
trimethoxyflavone		antiemetic;
plant metabolite
n-cinnamoyltyramine
N-cinnamoyltyramine: isolated from Lycianthes biflora; structure in first source. N-trans-cinnamoyltyramine : A member of the class of cinnamamides that is tyramine substituted by a (1E)-3-oxo-1-phenylprop-1-en-3-yl group at the nitrogen atom. It is found in rice and exhibits an allelopathic effect to suppress the growth of weeds.		2.1310cinnamamides;
phenols;
secondary carboxamide		allelochemical;
antimicrobial agent;
phytoalexin;
platelet aggregation inhibitor
n-(4-hydroxy-beta-phenethyl)-4-hydroxycinnamide
trans-N-p-coumaroyl tyramine: from the twigs of Celtis chinensis; structure in first source		3.0540hydroxycinnamic acidmetabolite
n-feruloylserotonin
N-feruloylserotonin: structure in first source. N-feruloylserotonin : A member of the class of hydroxyindoles that is the N-feruloyl derivative of serotonin.		2.0510aromatic ether;
cinnamamides;
hydroxyindoles;
phenols;
secondary carboxamide		plant metabolite
3-tyrosine
3-tyrosine: RN given refers to cpd with unspecified isomeric designation. L-m-tyrosine : A hydroxyphenylalanine that is L-phenylalanine with a substituent hydroxy group at position 3.		2.0110hydroxyphenylalanine;
L-alpha-amino acid zwitterion;
L-phenylalanine derivative;
non-proteinogenic L-alpha-amino acid;
phenols		plant metabolite
n-caffeoyldopamine
N-caffeoyldopamine: structure in first source		2.4320
ks370g
KS370G: antihyperglycemic; structure in first source		2.0310
n-coumaroyldopamine
N-coumaroyldopamine: structure in first source		2.1310
miliusol
miliusol: from Miliusa balansae; structure in first source		2.1310
feruloyldopamine
feruloyldopamine: a dopamine metabolite isolated from tomatoes after infection by Pseudomonas syringae; structure in first source		2.0310
dihydro-n-caffeoyltyramine
dihydro-N-caffeoyltyramine: structure in first source		2.7330catechols
n-trans-feruloyloctopamine
N-feruloyloctopamine: has antifungal activity; isolated from root bark of Lycium chinense; structure in first source		2.4620methoxybenzenes;
phenols
ConditionIndicatedRelationship StrengthStudiesTrials
Incontinentia Pigmenti Achromians
[description not available]		02.0310
Malignant Melanoma
[description not available]		02.0510
B16 Melanoma
[description not available]		02.0510
Melanoma
A malignant neoplasm derived from cells that are capable of forming melanin, which may occur in the skin of any part of the body, in the eye, or, rarely, in the mucous membranes of the genitalia, anus, oral cavity, or other sites. It occurs mostly in adults and may originate de novo or from a pigmented nevus or malignant lentigo. Melanomas frequently metastasize widely, and the regional lymph nodes, liver, lungs, and brain are likely to be involved. The incidence of malignant skin melanomas is rising rapidly in all parts of the world. (Stedman, 25th ed; from Rook et al., Textbook of Dermatology, 4th ed, p2445)		02.0510
Infections, Plasmodium
[description not available]		02.1310
Malaria
A protozoan disease caused in humans by four species of the PLASMODIUM genus: PLASMODIUM FALCIPARUM; PLASMODIUM VIVAX; PLASMODIUM OVALE; and PLASMODIUM MALARIAE; and transmitted by the bite of an infected female mosquito of the genus ANOPHELES. Malaria is endemic in parts of Asia, Africa, Central and South America, Oceania, and certain Caribbean islands. It is characterized by extreme exhaustion associated with paroxysms of high FEVER; SWEATING; shaking CHILLS; and ANEMIA. Malaria in ANIMALS is caused by other species of plasmodia.		02.1310
Acute Confusional Senile Dementia
[description not available]		02.3110
Alzheimer Disease
A degenerative disease of the BRAIN characterized by the insidious onset of DEMENTIA. Impairment of MEMORY, judgment, attention span, and problem solving skills are followed by severe APRAXIAS and a global loss of cognitive abilities. The condition primarily occurs after age 60, and is marked pathologically by severe cortical atrophy and the triad of SENILE PLAQUES; NEUROFIBRILLARY TANGLES; and NEUROPIL THREADS. (From Adams et al., Principles of Neurology, 6th ed, pp1049-57)		02.3110
Extravascular Hemolysis
[description not available]		02.0210
Hemolysis
The destruction of ERYTHROCYTES by many different causal agents such as antibodies, bacteria, chemicals, temperature, and changes in tonicity.		02.0210